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Carcinogenicity Studies in Rodents with Ripazepam, a Minor Tranquilizing Agent. FITZGERALD, 
J. E., DE LA IGLESIA, F. A., AND MCGJIRE, E. J. (1984). Fundam. Appl. Pharmacol. 4, 178- 
190. The carcinogenesis potential of ripazepam, a benzodiazepine derivative, was studied in mice 
and rats for 78 and 104 weeks, respectively. Groups of 50 male and 50 female CD1 mice and 
CD rats each were given doses of 15 and 150 mg/kg of ripazepam in the diet. Survival rates 
were adequate for statistical analysis. Significant suppression of body weight gains occurred in 
rats but not in mice given 150 mg/kg/day. The compound failed to increase tumor rates or alter 
the average latency of neoplasms in the rat. In mice, the number of male animals with tumors 
was increased at 150 mg/kg and this was related to a significant increase in the number of animals 
with hepatocellular tumors. Hepatocellular tumors were increased also in female mice but the 
increase was not statistically significant. All but one of these hepatic neoplasms were hepatocellular 
adenomas and the one carcinoma had not metastasized. Other tumor types were not increased. 
Ripazepam, also recognized as CL683 or Pyr- 
azapon, is a pyrazolodiazepinone which has 
demonstrated anxiolytic effects in animal 
pharmacologic tests. It is identified chemically 
as 1-ethyl-4,6-dihydro-3-methyl-8-phenylpyr- 
azolo[4,3,e][ 1,4]diazopine and is structurally 
related to other diazopinone (Fig. 1) deriva- 
tives such as diazepam, oxazepam, and pra- 
zepam. 
The pharmacologic profile of the compound 
was determined previously in mice, rats, 
monkeys, and rabbits (Poschel et al., 1974). 
In animal tests, ripazepam had the desired 
properties of a potent antianxiety effect with- 
out strong sedative or depressant activity. 
The toxicity of diazepines has been reviewed 
(Randall et al., 1974) and effects on repro- 
duction and development have been investi- 
gated (Fox, 1975; Guerriero and Fox, 1976); 
however, only a few carcinogenesis bioassays 
with this class of compound are available. In 
a limited study, hepatic cell adenomas and 
peliosis hepatis were reported in mice follow- 
ing the feeding of oxazepam for several months 
(Fox and Lahcen, 1974). More recently, pra- 
zepam at multiple dose levels and diazepam 
at one dose level were not carcinogenetic (de 
la Iglesia et al., 1981). 
METHODS 
Chemical. Pharmaceutical grade ripazepam was sup 
plied as a pale yellow crystalline solid with a melting point 
of 220-222.5”C. Purity assays indicated that the com- 
pound was 100% active base. The structure of ripazepam 
is shown in Fig. 1. 
Animals and housing. Barrier raised animals of both 
sexes were used. Random bred albino CD strain rats and 
albino CD1 mice were supplied by Charles River Breeding 
Laboratories, Wilmington, Massachusetts. The animals 
were approximately 5 to 6 weeks of age at study initiation. 
Animal housing and care conformed to recommendations 
of HEW Publication (NIH) 74-73. Rats were housed in- 
dividually in stainless-steel wire mesh cages and mice were 
housed individually in solid bottom suspended cages con- 
taining wood shavings as bedding material. The animals 
were maintained in rooms with controlled temperature 
and relative humidity with frequent fresh air exchanges 
and a 12-hr photoperiod. Body weights and feed con- 
sumption were measured weekly. From these data, the 
concentration of drug in the diet was adjusted weekly to 
compensate for changes in body weight and feed con- 
sumption. Drug/diet admixtures were prepared fresh each 
week and were offered ad libitum. Fresh water was freely 
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FIG. 1. Structural formula of ripazepam. Clinical Observations and Nonneoplastic Le- 
available. All animals were observed daily for signs of 
toxic reactions. Physical examinations were performed 
weekly at the time of transfer of animals to clean cages. 
Ophthalmic examinations were performed pretest and at 
intervals of 1 to 3 months during the study. 
Experimental groups. Dose levels selected ,for these 
experiments were based on an overall assessment of the 
effects found in previous acute, subacute, and l-year oral 
feeding studies. Groups of 50 rats and 50 mice of each 
sex were fed ripazepam at 15 and 150 mg/kg body wt. 
Additional groups of 50 rats and 50 mice of each sex 
served as untreated controls. 
Pathology studies. Animals found moribund or in an 
extreme debilitated condition were killed for humane rea- 
sons and to minimize the onset of autolytic changes in 
the event of death. All animals were necropsied and those 
killed because of debilitating clinical condition were con- 
sidered deaths for the purposes of data analysis. For animals 
killed at termination of the study, organ weights and organ 
to body weight ratios were determined for brain and liver. 
Following gross examinations, all major organs and gross 
abnormalities were processed from all animals and eval- 
uated microscopically. 
Methods of tumor analysis. All tumors including those 
noted upon gross examination were subjected to micro- 
scopic confirmation. The procedure for analyzing the tu- 
mor incidence in both species has been described elsewhere 
(de la Iglesia ef al., 198 1). Briefly, tumor analysis employed 
a life-table technique to analyze the occurrence of tumors 
and estimate differences in significance and probability 
levels between test groups. This technique considers time- 
response data, tumor induction, and correction for ex- 
traneous deaths. Tumor incidence was evaluated also using 
Fisher’s Exact Test in both species and the Armitage Dose- 
Trend test in rats. 
RESULTS 
sions 
Survival curves for mice and rats fed ri- 
pazepam are shown in Figs. 2 and 3, respec- 
tively. A sufficient number of animals was 
available for statistical analysis at the com- 
pletion of the studies. 
There were no significant clinical signs or 
ophthalmologic findings in either mice or rats. 
Body weight gain was suppressed by 2 1% in 
male and 36.4% in female rats given 150 mg 
ripazepam/kg indicating that maximally tol- 
erable concentrations were administered. Feed 
consumption was decreased slightly (7%) only 
in female rats at the 150-mg/kg dose. In treated 
mice, body weight gain exceeded that of un- 
treated controls at both doses in females and 
at the 15-mg/kg dose in the males. Feed con- 
sumption was not significantly different be- 
tween treated and control mice. At necropsy, 
the mean weight of the liver of male mice was 
significantly increased at the 150-mg/kg dose 
level compared to that of untreated control 
mice (Table 1). In rats, weights of the liver 
TABLE 1 








Mouse 0 7.61 f 0.36 6.45 + 0.23 45.29 f 1.38 37.97 + 0.88 
15 6.49 f 0.37 7.69 + 0.28 49.22 f 1.99 40.58 + 1.33 
150 13.86 I!Z 1.58* 7.63 + 0.62 44.78 + 0.80 39.56 + 1.12 
Rat 0 4.38 + 0. I1 5.80 + 0.21 571.46 f 10.31 440.85 k 10.99 
15 5.21 + 0.15’ 6.00 f 0.17 544.20 f 15.10 445.06 k 1 I .40 
150 7.53 + 0.23. 7.87 f 0.29 505.84 + 9.99* 350.22 f 14.90: 
’ Values expressed in g (body weights) or g% (liver weights), mean ? SE. 
* Values significantly different from control (p < 0.01). 
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FIG. 2. Probability of survival of mice given ripazepam in the diet for 78 weeks. 
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FIG. 3. Probability of survival of rats given ripazepam in the diet for 104 weeks. 
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TABLE 2 
DISTRIBUTION OF TUMOR TYPES IN MICE GIVEN 
RIPAZEPAM ORALLY FOR 78 WEEKS 
Sex: Males Females 
Dose (mg/kg): 
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were significantly increased on a dose re- 
lated basis in males and in females given 
150 mg/kg. 
A variety of nonneoplastic pathologic 
changes were observed in both treated and 
control mice. These lesions were primarily de- 
generative or inflammatory in nature and most 
were considered incidental and related to ag- 
ing. The incidence of atria1 thrombosis was 
20% in males of the 150-mg/kg group com- 
pared to 0.8% in males of the 1 Smg/kg group 
and 4% in untreated control males. Atrophy 
of the ovaries was seen in 90% of the females 
of the 150-mg/kg group in 46% of the 15-mg/ 
kg animals and in 54% of the controls. Other 
lesions occurred in comparable incidences be- 
tween treated and control mice. 
Microscopically, nonneoplastic changes as- 
sociated with drug treatment in rats included 
centrolobular hypertrophy of hepatocytes 
principally at the 150-mg/kg dose. Enlarged 
hepatocytes stained more intensely with eosin 
and in a few high dose rats the cytoplasm had 
a hyaline or “ground glass” appearance. Other 
alterations included increased incidences of 
focal accumulations of pulmonary alveolar 
macrophages in both dose groups and dila- 
tation of tubules in the renal cortex and fol- 
licular hyperplasia in the thyroid; these last 
two changes were more common in male rats 
of the 150-mg/kg group. 
A variety of other lesions occurred in similar 
incidences in both control and treated rats. 
Neoplasms in Mice 
A summary of the various neoplasms found 
in treated and control mice is given in Table 
2. Tumors of the lungs, liver, and lymphoid 
organs were the most frequently occurring 
neoplasms in both sexes. 
Total tumor incidence and tumor latency 
data are summarized in Tables 3 and 4. The 
incidences of all tumor types, except hepa- 
tocellular adenomas, were not statistically dif- 
ferent between treated and control groups. 
Hepatocellular adenomas (also considered as 
neoplastic nodules) were increased in both 
sexes given 150 mg/kg but not in those groups 
given 15 mg/kg. The increased incidence of 
hepatic cell tumors was statistically significant 
(p -C 0.05) only in the high dose male mice. 
Latency periods for hepatic and other tumor 
types were comparable. The incidence of other 
benign tumors was not significantly increased 
in the 150-mg/kg group. No increase in tumors 
was found in the 15-mg/kg group. The number 
of malignant neoplasms was increased in 
males of the low dose group but this was con- 
sidered unrelated to compound administration 
because of the lack of a dose-response rela- 
tionship. 
Hepatocelluiar adenomas varied from a 
single small nodule to large masses involving 
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TABLE 3 
TOTAL TUMOR INCIDENCE IN MICE GIVEN RIPAZEPAM ORALLY FOR 78 WEEKS 
sex: Males Females 
he bdc3): 0 15 150 0 15 150 
Animals/group 50 50 50 50 50 50 
Incidence of all 
tumors” 28 39 46 13 13 24 
Animals with 
tumors 24 31 39 12 13 21 
Animals with 4 
malignant tumors - [4.6!2]** [0.0:61] 2 [1.8;37] [1.4;66] 
Animals with 21 
benign tumors - [0.1::2] [l5.z49]* ” [1.99630] $341 
’ These figures include multiple tumor types found in individual animals, but do not include multiple tumors of 
the same type. They are not, therefore, true incidences and cannot be expressed as percentages. Statistical determinations 
were not performed on these figures. 
* Significantly different (p < 0.01) from control. Chi-square values indicated in brackets. 
** Significantly different (p < 0.05) from control, 
entire lobes. Multiple nodules occurred more 
frequently in treated than in control mice. 
Microscopically, a few tumors consisted of 
nodules of well differentiated but somewhat 
smaller hepatocytes than those in adjacent 
normal areas of the liver. Most specimens, 
however, contained enlarged hepatocytes or a 
combination ofsmall and large cells (Fig. 4). 
Hepatocellular adenomas were confined by 
the liver capsule; neither local invasion nor 
metastasis occurred (Figs. 5 and 6). One he- 
patic cell tumor from a male given 150 mg/ 
kg consisted of sheets of anaplastic cells with 
vesiculated nuclei and was considered cyto- 
logically a carcinoma (Fig. 7). 
Neoplasm in Rats 
Data related to tumor types, incidences, and 
average latency are summarized in Tables 5, 
6, and 7. The most frequently occurring neo- 
plasms in both male and female rats were ad- 
renal cortical adenomas, hepatocellular ad- 
enomas (neoplastic nodules), and pituitary 
adenomas. Mammary gland adenomas and 
fibroepithelial tumors were common in female 
rats. No significant dose related differences in 
tumor types, average latency, tumor onset, or 
in overall tumor incidences between treated 
and control rats were observed. 
DISCUSSION 
From the results of this study it appears 
that ripazepam does not elicit a tumorigenic 
potential in rats when administered at a max- 
imally tolerated dose of 150 mg/kg for 2 years. 
In mice, a comparable dose given for 18 
months resulted in an increased incidence of 
hepatocellular adenomas, a frequent tumor in 
this species. The latency period for hepatic 
tumors was not affected by treatment and 
other tumor types were not increased signif- 
icantly in the mouse. 
Interestingly, ripazepam produced a similar 
increase in the weight of the liver in both ro- 
dent species, although a tumorigenic response 
was evoked in the liver only in the mouse and 
only at a dose of 150 mg/kg. 
A I O-fold lower dose of 15 mg/kg did not 
increase significantly the number of hepato- 
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TABLE 4 
AVERAGE LATENCY PERIOD (WEEKS) OF MOST COMMON TUMORS IN MICE FED RIPAZEPAM FOR 78 WEEKS 















Onset fin brackets] expressed as week when first tumor detected, average latency expressed as arithmetic mean of 
onset weeks/tumor bearing animals, M: males; F: females. 
cellular tumors suggesting a threshold effect. 
Hepatomegaly has been observed previously 
in rodents given other diazopinones (Fox and 
Lahcen, 1974; Kuriyama et al., 1978; de la 
Iglesia et al., 198 1). The increase in liver weight 
was correlated with an increase in drug me- 
tabolizing enzymes and smooth endoplasmic 
reticulum- in hepatic cells (Kuriyama et a/., 
1978). There was a higher incidence of non- 
neoplastic changes in the heart and ovaries in 
mice and in the lung and kidneys in rats, but 
these lesions are not uncommon in aged ro- 
dents and were considered to represent a 
skewed distribution rather than a direct drug 
effect. 
Only a few reports concerning the carci- 
nogenic potential of benzodiazepines have 
been published, although these drugs have 
been used extensively for several years. He- 
patic cell adenomas and peliosis hepatis were 
reported in mice fed up to 0.15% oxazepam 
(estimated to yield about 2 10 mg/kg) for a 
year (Fox and Lahcen, 1974). Data on the 
chronic administration of oxazepam to rats 
are not available for comparison purposes. 
However, closely related compounds such as 
diazepam and prazepam have been studied 
for 104 weeks in rats and 80 weeks in mice 
and neither compound was tumorigenic in 
either species (de la Iglesia et al., 198 1). In 
other studies, diazepam was without signifi- 
cant effects in rats given doses of up to 240 
mg/kg for 42 weeks (Randall et al., 1961). 
Chlordiazepoxide was administered to rats 
at doses of up to 240 mg/kg for most of their 
life span and the compound was reported to 
be innocuous. However, no definitive data on 
tumor incidences were provided (Zbinden et 
al., 1961). 
Carcinogenesis in the rat liver has been re- 
ported to be accompanied by focal alterations 
in such hepatocellular enzymes as ATPase. 
FIG. 4. Liver section from a male mouse fed 150 mg&g of ripazepam for 78 weeks. Liver cell adenoma 
consisting of hypertrophic hepatocytes (arrows) is well delineated from normal parenchyma. X 100. 
FIG. 5. Hepatocellular adenoma from male mouse fed 150 me/kg of ripazepam. Tumor involves a large 
area of the Iobe @TOWS) but is confined within the liver capsule. X40. 
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FIG. 6. A small hepatocellular adenoma consisting of cords of enlarged hepatocytes that form a well 
delineated nodule (arrows). X40. 
FIG. 7. Hepatccellular carcinoma from a male mouse fed 150 mg/kg of ripazepam showing sheets of 
anaplastic hepatocytes with vesiculated nuclei. X250. 
RIPAZEPAM CARCINGGENESIS 187 
TABLE 5 
DISTRIBUTION OF TUMOR TWES IN RATS GIVEN RIPAZEPAM ORALLY FOR 104 WEEKS 
Sex: Males Females Sex: Males Females 
Dose (ma): 0 15 150 0 15 150 Dose (mg/kg): 0 15 150 0 15 150 
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Diethylnitrosamine administration resulted in in the liver, rats were fed 3’-methyl4-(di- 
an increase in ATPase deficient foci in the methylamino)azobenzene at a concentration 
liver of rats but not mice (Laib et al., 1982). of 0.06% for 3 weeks followed by 0.05% di- 
In a similar assay for tumor promoting effects azepam for an additional 13 weeks. Diazepam 
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TABLE 6 
TOTAL TUMOR INCIDENCE 1~ RATS GIVEN RIPAZEPAM ORALLY FOR 104 WEEKS 
Males Females 
Sex: 
Dose (mg/kg): 0 15 150 0 15 150 
Animals/group 
Incidence of all tumors“ 





50 50 50 50 50 50 
58 14 76 142 119 131 
40 43 47 48 47 46 
I 
- [l.d3095] [1.:6040] 9 [0.05:9] [2.5d:2] 
36 
- [O.&l [O.&l [0.0?59] 
’ These figures include multiple tumor types found in individual animals, but do not include multiple tumors of 
the same type. They are not, therefore, true incidence and cannot be expressed as percentages. Statistical determinations 
were not performed on these figures. 
* Chi-squares values indicated in brackets; values not significantly different from control. 
did not increase the number or size of ATPase 
deficient foci in the liver indicating that the 
compound was not a promoter of hepatocar- 
cinogenesis in the rat (Hino and Kitagawa, 
1982). In other short term assays diazepam, 
clorazepate, oxazepam, and lorazepam did not 
initiate preneoplastic or neoplastic foci in the 
liver when administered orally to rats for 14 
weeks. Further, these diazepines did not pro- 
mote or enhance the neoplastic foci initiated 
in the livers of rats with N-2-fluorenylacetam- 
ide (Mazue et al., 1982). Thus, most available 
reports on the chronic administration of ben- 
zodiazepines suggest that these compounds are 
not tumorigenic. Perhaps this failure to induce 
hepatic cell or other neoplasms is related to 
the extensive biotransformation of the com- 
pounds by hepatocytes ‘(Viau et al., 1972, 
1973). We have investigated the possibility that 
these tumors be the result of direct genotoxic 
insult, and ripazepam did not induce rever- 
tants in the standard bacterial plate assay with 
five strains of Salmonella typhimurium (un- 
published data). Several benzodiazepines have 
been evaluated for potential mutagenicity with 
equivocal results, including diazepam and ox- 
azepam which were not mutagenic in bacteriaI 
assays with four salmonella strains (Balbi et 
al., 1980). The urine of mice treated with di- 
azepam, however, was reported to increase 
revertants in two strains of salmonella (Bat- 
zinger et al., 1978). No chromosomal aber- 
rations or breaks have been found in several 
in vitro, in vivo animal or human studies with 
diazepines (Staiger, 1969, 1970; White, 1974; 
Neda et al., 1977; Schmid and Staiger, 1969; 
Cohen et al., 1969). However, chlordiazepox- 
ide was reported to induce sex-linked recessive 
lethality and translocation in drosophila (San- 
jeeva Rao and Pratays, 1974), and increased 
dominant lethality in mice (Prabhakar Rao 
and Sanjeeva Rao, 1977), whereas diazepam 
produced chromosomal breaks in mouse bone 
marrow cells (Petersen et al., 1978). 
The benzodiazepines are compounds with 
similar pharmacological properties and the 
collective evaluation of experimental studies 
yields equivocal results. Based on the results 
of this study with ripazepam and published 
data on related compounds it appears that the 
structural similarities of these compounds are 
not predictive of the potential for tumor in- 
duction in rodents, nor are these effects clearly 
elucidated in mechanistic studies using genetic 
endpoints (de la Iglesia et al., 198 1; Mazue et 
al., 1982). 
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TABLE I 
EARLIEST ONSET AND AVERAGE LATENCY PERIOD OF COMMON TUMORS 
JN RATS FED BJPAZEPAM FOR 104 WEEKS 
Tumor type 
Bipaxepam dose (mg/kg/day) 
150 15 Controls 
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Note. Onset [in brackets] expressed as week when first tumor detected; average latency expressed as arithmetic 
mean of onset weeks/tumor bearing animals; M, males, F, females. 
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